Publicaciones científicas

Búsqueda avanzada

Inicio
> Grupos de Investigación
> Área de Cáncer
> Laboratorio de oncología molecular y celular

Laboratorio de oncología molecular y celular

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia , 27: 430-440. FI: 9,561 (Q1) (D1)
PubMed
Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance
Ocaña A, Cruz JJ, Pandiella A.
American Journal of Clinical Oncology -Cancer Clinical Treatment 29(1):90-5. FI: 2.206 (Q3)
PubMed
An update into the pathophysiological role of HER2 in cancer: therapeutic implications
Ocaña A, Pandiella A.
Clinical & Translational Oncology 9(9):543-4. FI: 1.146 (Q4)
PubMed
Cellular expression levels of the vitamin D receptor are critical to its transcriptional regulation by the pituitary transcription factor Pit-1
Seoane S, Ben I, Centeno V, Perez-Fernandez R.
Molecular Endocrinology 21(7):1513-25. FI: 5.257 (Q1)
PubMed
Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis
Borges J, Pandiella A, Esparís Ogando A.
Cell Signal 19(7):1473-87. FI: 4.094 (Q2)
PubMed
The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function
Montero JC, Rodríguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparís Ogando A, Pandiella A.
Molecular Biology of the Cell 18(2):380-93. FI: 5.979 (Q1)
PubMed
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer
de Alava E, Ocaña A, Abad M, Montero JC, Esparís Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A.
Journal of Clinical Oncology 25(19):2656-63. FI: 17.793 (Q1)
PubMed
Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis
Ramirez JM, Ocio EM, San Miguel JF, Pandiella A.
Leukemia 21(4):797-804. FI: 8.296 (Q1)
PubMed
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
Cruz JJ, Ocaña A, Del Barco E, Pandiella A.
Annals of Oncology 18(3):421-30. FI: 5.647 (Q1)
PubMed
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Esparís Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A.
Annals of Oncology 19(11):1860-9. FI: 5.647 (Q1)
PubMed

45 resultados

Páginas: 1 2 3 4 5 >

NoticiasNoticias
Zona del InvestigadorZona del Investigador